

Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	27.4	69.3	(41.7-108.2)	Male	27	17.8	151.5	(99.8-220.5)
Female	11	9.8	112.7	(56.2-201.6)	Female	15	13.5	111	(62.1-183.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.3	113.4	(41.4-246.8)	Male	4	4.9	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	Female	7	3.9	178.6	(71.6-368)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	12	15.7	76.2	(39.3-133.1)
Female	127	102.3	124.2	(103.5-147.8)	Female	13	12.6	103	(54.8-176.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.6	139.8	(45-326.2)	Male	10	11.8	84.6	(40.5-155.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	30	31.2	96.1	(64.8-137.2)	Female	10	9.3	108.1	(51.8-198.8)
Female	36	30.9	116.4	(81.5-161.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	9	133.3	(68.8-232.8)
Male	6	7.3	82	(29.9-178.5)	Female	9	9.4	95.3	(43.5-180.8)
Female	1	2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	111	100.6	110.3	(90.8-132.9)
Male	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.6	nc	(nc-nc)	Male	6	6.5	92.2	(33.7-200.7)
<u>Kidney & Renal Pelvis</u>					Female	3	3.8	nc	(nc-nc)
Male	17	14.6	116.4	(67.8-186.4)	<u>Testis</u>				
Female	4	8.2	nc	(nc-nc)	Male	6	3.4	176	(64.3-383)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	4	149.9	(54.8-326.4)	Male	6	6.5	92.8	(33.9-202)
Female	0	1.2	nc	(nc-nc)	Female	18	18.3	98.2	(58.2-155.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	10.7	65.7	(26.3-135.4)	Female	25	23.2	107.7	(69.6-158.9)
Female	6	7.6	78.6	(28.7-171.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	368	366.1	100.5	(90.5-111.3)
Male	6	8.5	70.2	(25.6-152.8)	Female	367	351	104.6	(94.1-115.8)
Female	3	2.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	45	49.6	90.7	(66.2-121.4)					
Female	44	49.7	88.6	(64.4-118.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	62	57.7	107.5	(82.4-137.8)	Male	36	38.7	93.1	(65.2-128.9)
Female	24	21.9	109.5	(70.2-163)	Female	22	32.4	67.8	(42.5-102.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	11.8	93.2	(46.5-166.8)	Male	13	10.4	125.4	(66.7-214.4)
Female	10	9.9	101.2	(48.5-186.1)	Female	4	8.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	29	34.1	84.9	(56.9-122)
Female	232	226.2	102.6	(89.8-116.7)	Female	30	28.7	104.4	(70.4-149)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	8.5	140.6	(72.6-245.7)	Male	28	24.9	112.3	(74.6-162.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	51	65.3	78.1	(58.1-102.6)	Female	26	21	123.9	(80.9-181.5)
Female	60	69.1	86.8	(66.2-111.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	15	15.4	97.4	(54.5-160.6)	Male	14	18.9	73.9	(40.4-124.1)
Female	4	4.4	nc	(nc-nc)	Female	28	21.2	132	(87.7-190.7)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	2	6.1	nc	(nc-nc)	Male	16	13.7	116.6	(66.6-189.4)
Female	7	4.8	144.6	(57.9-297.9)	Female	9	8.5	105.8	(48.3-200.8)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	34	31	109.6	(75.9-153.1)	Male	11	11	100.2	(49.9-179.2)
Female	12	18.4	65.3	(33.7-114)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	8.4	83	(33.3-171)	Female	45	51.9	86.8	(63.3-116.1)
Female	1	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Female</u>				
Male	18	23	78.2	(46.3-123.5)	Male	725	783	92.6	(86-99.6)
Female	14	17.5	80	(43.7-134.2)	Female	767	795.2	96.4	(89.7-103.5)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	18	17.9	100.4	(59.5-158.7)					
Female	5	6.4	78.2	(25.2-182.4)					
<u>Lung and Bronchus</u>									
Male	116	104.7	110.8	(91.5-132.9)					
Female	108	112	96.4	(79.1-116.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.6	86.4	(41.4-159)	Male	5	7.5	66.7	(21.5-155.5)
Female	5	4.3	116.8	(37.7-272.7)	Female	4	5.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.2	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.6	106.2	(42.5-218.8)
Female	29	43.4	66.9	(44.8-96)	Female	6	5.5	109	(39.8-237.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.5	nc	(nc-nc)	Male	5	5	100.2	(32.3-233.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	13.1	107	(58.4-179.5)	Female	3	4	nc	(nc-nc)
Female	13	13.5	96.1	(51.1-164.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	3.8	209.9	(90.4-413.7)
Male	3	3.1	nc	(nc-nc)	Female	5	4.1	120.5	(38.8-281.2)
Female	1	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	39	43.3	90	(64-123)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	2.7	182.1	(58.7-424.9)
<u>Kidney & Renal Pelvis</u>					Female	0	1.7	nc	(nc-nc)
Male	5	6.1	81.6	(26.3-190.4)	<u>Testis</u>				
Female	8	3.5	227	(97.8-447.4)	Male	1	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	1.7	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	7.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.5	nc	(nc-nc)	Female	7	10	70.1	(28.1-144.4)
Female	1	3.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	140	155.2	90.2	(75.9-106.5)
Male	3	3.6	nc	(nc-nc)	Female	125	151.7	82.4	(68.6-98.2)
Female	1	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	21	76.1	(43.5-123.7)					
Female	15	21.7	69.2	(38.7-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	27.8	151	(108.8-204.1)	Male	10	17.7	56.4	(27-103.8)
Female	12	9.8	121.9	(62.9-212.9)	Female	13	13.6	95.7	(50.9-163.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5	nc	(nc-nc)	Male	7	5	139.9	(56.1-288.3)
Female	4	4.2	nc	(nc-nc)	Female	1	4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	15	15.4	97.1	(54.3-160.2)
Female	92	103.2	89.2	(71.9-109.4)	Female	7	12.8	54.9	(22-113.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.5	nc	(nc-nc)	Male	16	11.7	136.2	(77.8-221.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	40	30.8	129.8	(92.7-176.7)	Female	13	9.4	138.4	(73.6-236.7)
Female	37	30.3	121.9	(85.8-168.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	13	9.2	141.9	(75.5-242.6)
Male	10	7.6	132.4	(63.4-243.5)	Female	15	9.5	158.6	(88.7-261.6)
Female	2	2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	102	106.8	95.5	(77.9-115.9)
Male	2	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.6	nc	(nc-nc)	Male	8	6.5	122.4	(52.7-241.2)
<u>Kidney & Renal Pelvis</u>					Female	1	3.7	nc	(nc-nc)
Male	20	14.6	137.3	(83.8-212)	<u>Testis</u>				
Female	7	8.4	83.8	(33.6-172.6)	Male	1	2.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	4.1	121	(39-282.3)	Male	4	6.1	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	17	18.2	93.4	(54.4-149.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	10.4	124.8	(66.4-213.4)	Female	25	24.3	102.8	(66.5-151.8)
Female	9	7.5	120.3	(54.9-228.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	435	372.2	116.9	(106.2-128.4)
Male	10	8.6	116.2	(55.6-213.7)	Female	392	354.7	110.5	(99.8-122)
Female	8	2.9	276.4	(119-544.6)					
<u>Lung and Bronchus</u>									
Male	85	51.4	165.3	(132.1-204.4)					
Female	80	51.8	154.5	(122.5-192.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.5	91.3	(29.4-213)	Male	2	3.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	2	1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	26	19.9	131	(85.5-191.9)	Female	1	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	6.3	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	2	5.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	1.8	383.3	(153.6-789.9)
Male	3	1.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	14	21.5	65.2	(35.6-109.4)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.7	nc	(nc-nc)
Male	3	3	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.6	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.2	nc	(nc-nc)	Female	6	4.5	132	(48.2-287.4)
Female	2	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	60	75.7	79.3	(60.5-102.1)
Male	3	1.8	nc	(nc-nc)	Female	65	66.6	97.6	(75.3-124.4)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	10.1	98.9	(47.3-181.8)					
Female	13	9.1	142.4	(75.8-243.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.1	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	4.1	123.1	(39.7-287.4)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	12	13.8	86.7	(44.7-151.4)
Male	0	0.3	nc	(nc-nc)	Female	11	11.4	96.3	(48-172.2)
Female	1	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	1.8	nc	(nc-nc)					
Female	1	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	2	0.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	3.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	6	10.3	58.5	(21.4-127.4)
Male	0	0.3	nc	(nc-nc)	Female	5	7.8	63.8	(20.5-148.8)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.3	nc	(nc-nc)					
Female	0	1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	35.8	128.5	(94.1-171.4)	Male	21	22.9	91.7	(56.7-140.1)
Female	12	14.9	80.4	(41.5-140.4)	Female	18	20.7	87	(51.5-137.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.6	151.1	(72.3-277.9)	Male	8	6.3	127.4	(54.9-251.1)
Female	9	6.2	145.1	(66.2-275.4)	Female	4	5.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	18	20.2	89.2	(52.9-141.1)
Female	139	146.4	94.9	(79.8-112.1)	Female	21	19.1	110.1	(68.1-168.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	5.4	166.4	(75.9-316)	Male	16	14.3	111.8	(63.8-181.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	43	39.5	108.8	(78.7-146.5)	Female	14	13.6	103.2	(56.4-173.1)
Female	38	46.9	81.1	(57.3-111.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	11.6	146.7	(85.4-234.9)
Male	7	9.2	76.3	(30.5-157.1)	Female	20	14.5	137.6	(84-212.5)
Female	3	3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	114	124.3	91.7	(75.6-110.1)
Male	2	3.1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.7	nc	(nc-nc)	Male	9	8.3	108	(49.3-205)
<u>Kidney & Renal Pelvis</u>					Female	6	5.8	103.5	(37.8-225.2)
Male	21	18.1	116.1	(71.9-177.5)	<u>Testis</u>				
Female	7	12.1	57.9	(23.2-119.3)	Male	6	5.5	109.7	(40.1-238.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	5	140.5	(56.3-289.4)	Male	12	8.2	146.4	(75.6-255.8)
Female	1	1.8	nc	(nc-nc)	Female	24	28.2	85	(54.4-126.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	13.6	58.8	(25.3-115.8)	Female	33	33.2	99.3	(68.3-139.5)
Female	13	11.4	113.9	(60.6-194.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	461	464.5	99.2	(90.4-108.7)
Male	11	10.4	105.4	(52.6-188.6)	Female	488	521.8	93.5	(85.4-102.2)
Female	6	4.3	140.9	(51.4-306.7)					
<u>Lung and Bronchus</u>									
Male	56	64	87.4	(66.1-113.6)					
Female	71	75.6	93.9	(73.3-118.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	16.8	53.6	(24.5-101.8)	Male	16	10.7	149.3	(85.3-242.4)
Female	6	5.5	108.5	(39.6-236.2)	Female	14	7.9	178	(97.2-298.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.1	nc	(nc-nc)	Male	4	3	nc	(nc-nc)
Female	7	2.4	286.2	(114.7-589.7)	Female	1	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	9.4	127.3	(65.7-222.5)
Female	77	61.5	125.1	(98.7-156.4)	Female	11	7.3	151.1	(75.3-270.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	3	7.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	18.9	58.1	(29-104)	Female	3	5.5	nc	(nc-nc)
Female	12	17.4	68.8	(35.5-120.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.5	90.8	(29.3-211.9)
Male	1	4.5	nc	(nc-nc)	Female	6	5.3	113.2	(41.3-246.4)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	64	63.3	101.1	(77.8-129.1)
Male	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.1	nc	(nc-nc)
Male	6	8.9	67.5	(24.7-146.9)	<u>Testis</u>				
Female	4	4.8	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.5	nc	(nc-nc)	Male	6	3.7	161.7	(59.1-352.1)
Female	0	0.7	nc	(nc-nc)	Female	16	10.8	148.1	(84.6-240.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.3	110.3	(44.2-227.3)	Female	8	14.3	56	(24.1-110.3)
Female	2	4.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	186	224	83	(71.5-95.9)
Male	3	5.3	nc	(nc-nc)	Female	206	205.7	100.1	(86.9-114.8)
Female	3	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	30.7	48.9	(27.3-80.6)					
Female	22	28.9	76.2	(47.7-115.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	19.9	165.7	(114-232.7)	Male	8	12.7	63.1	(27.2-124.4)
Female	9	7.8	115.7	(52.8-219.7)	Female	4	10.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	0.6	nc	(nc-nc)	Male	11	11.2	98.1	(48.9-175.5)
Female	79	74.6	105.9	(83.9-132)	Female	8	9.8	81.8	(35.2-161.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	5	8.3	60.6	(19.5-141.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	22.3	116.6	(76.2-170.9)	Female	7	7	100.7	(40.3-207.5)
Female	34	24.8	137.3	(95.1-191.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	7	5.2	134.3	(53.8-276.6)	Male	7	6.5	107.9	(43.2-222.3)
Female	0	1.6	nc	(nc-nc)	Female	4	7.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	3	1.5	nc	(nc-nc)	Male	5	4.7	106.9	(34.5-249.5)
Female	0	1.3	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	8	10.2	78.3	(33.7-154.2)	Male	1	2.5	nc	(nc-nc)
Female	6	6.1	97.9	(35.7-213)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.8	nc	(nc-nc)	Female	18	16.9	106.7	(63.2-168.7)
Female	2	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	7.6	144.2	(71.9-257.9)	Male	288	261	110.3	(98-123.8)
Female	9	6	150.2	(68.5-285.1)	Female	280	266.1	105.2	(93.3-118.3)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	6	6	99.9	(36.5-217.5)					
Female	6	2.2	273.3	(99.8-595)					
<u>Lung and Bronchus</u>									
Male	45	35.7	126.1	(92-168.8)					
Female	39	38	102.6	(72.9-140.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	29.1	82.5	(52.9-122.8)	Male	24	18.7	128.7	(82.4-191.5)
Female	9	10.9	82.8	(37.8-157.1)	Female	28	15.5	180.7	(120.1-261.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.5	90.5	(29.2-211.2)	Male	3	5.3	nc	(nc-nc)
Female	4	5	nc	(nc-nc)	Female	5	4.4	114.4	(36.9-266.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	21	16.5	127.5	(78.9-194.9)
Female	123	114.2	107.7	(89.5-128.5)	Female	18	14.2	126.7	(75.1-200.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.9	nc	(nc-nc)	Male	5	12.6	39.8	(12.8-92.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	32.9	54.7	(32.4-86.5)	Female	9	10.5	85.9	(39.2-163.1)
Female	22	34.5	63.8	(40-96.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	7.9	nc	(nc-nc)	Male	8	9.6	83.5	(35.9-164.4)
Female	2	2.2	nc	(nc-nc)	Female	8	10.5	76.1	(32.8-150)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	2	2.1	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
Female	6	2.2	268.8	(98.1-585)	Female	3	4.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	9	15.5	58.2	(26.6-110.6)	Male	4	3	nc	(nc-nc)
Female	8	9.2	87.1	(37.5-171.7)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	4.3	nc	(nc-nc)	Female	22	26	84.5	(52.9-127.9)
Female	1	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Female</u>				
Male	7	11.3	62.2	(24.9-128.1)	Male	338	389.6	86.8	(77.7-96.5)
Female	14	8.8	159.5	(87.1-267.6)	Female	373	394.5	94.5	(85.2-104.6)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	7	9.1	76.6	(30.7-157.8)					
Female	2	3.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	53.1	37.7	(23-58.2)					
Female	33	55.5	59.4	(40.9-83.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.1	155.9	(67.1-307.2)	Male	3	3	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	20	17.1	117.1	(71.5-180.9)	Female	3	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	5.5	218.1	(112.6-381)	Female	3	1.6	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.7	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	23	18.3	125.7	(79.7-188.7)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.6	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.8	nc	(nc-nc)	Female	1	4.1	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	67	64.7	103.5	(80.2-131.4)
Male	2	1.5	nc	(nc-nc)	Female	62	59.7	103.9	(79.7-133.2)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	9.3	nc	(nc-nc)					
Female	9	9.2	97.7	(44.6-185.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	3.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	5	4.5	112.1	(36.1-261.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.4	nc	(nc-nc)	Male	15	14.6	103.1	(57.6-170)
Female	1	0.1	nc	(nc-nc)	Female	8	11.9	67	(28.9-132)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	3	1.8	nc	(nc-nc)					
Female	3	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.1	97.9	(31.6-228.5)	Male	7	3.2	220.3	(88.2-453.9)
Female	4	1.7	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	19	17.8	106.7	(64.2-166.6)	Female	1	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	5.6	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	5	5.5	91.5	(29.5-213.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	21	17.8	118	(73-180.3)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.7	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Testis</u>				
Female	4	1.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.7	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.9	nc	(nc-nc)	Female	5	4	124.2	(40-289.8)
Female	3	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	61	65.9	92.6	(70.8-119)
Male	2	1.5	nc	(nc-nc)	Female	67	62.3	107.5	(83.3-136.5)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	9.2	54.5	(17.6-127.2)					
Female	8	8.9	89.5	(38.6-176.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	10.2	127.6	(67.9-218.3)	Male	4	6.6	nc	(nc-nc)
Female	6	3.3	183.9	(67.2-400.4)	Female	1	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.9	152.8	(69.7-290.1)
Female	35	31.8	110.1	(76.7-153.1)	Female	2	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	11.7	42.9	(13.8-100.1)	Female	3	2.9	nc	(nc-nc)
Female	7	10.3	68.1	(27.3-140.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.3	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	28	36.5	76.7	(51-110.9)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.3	nc	(nc-nc)
Male	5	5.4	93.2	(30-217.4)	<u>Testis</u>				
Female	3	2.6	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.5	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	7	5.4	130.4	(52.3-268.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.9	nc	(nc-nc)	Female	5	7.2	69.1	(22.3-161.3)
Female	1	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	113	135.2	83.6	(68.9-100.5)
Male	2	3.2	nc	(nc-nc)	Female	108	111.9	96.5	(79.2-116.6)
Female	2	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	18.2	98.8	(58.5-156.2)					
Female	17	16.3	104.3	(60.7-167)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.4	106.2	(50.8-195.3)	Male	6	5.9	102.4	(37.4-222.9)
Female	4	3.4	nc	(nc-nc)	Female	5	4.4	113	(36.4-263.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	22	33.3	66.1	(41.4-100.2)	Female	6	4.3	139.4	(50.9-303.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	10.3	77.3	(33.3-152.3)	Female	3	3.1	nc	(nc-nc)
Female	16	10.8	148.8	(85-241.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.1	nc	(nc-nc)
Male	5	2.4	204.1	(65.8-476.4)	Female	3	3.3	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	32	33.6	95.2	(65.1-134.4)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.3	nc	(nc-nc)
Male	6	4.7	127.2	(46.4-276.8)	<u>Testis</u>				
Female	0	2.7	nc	(nc-nc)	Male	3	1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.3	nc	(nc-nc)	Male	5	2	253.6	(81.7-591.9)
Female	1	0.4	nc	(nc-nc)	Female	6	5.6	106.7	(39-232.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.5	nc	(nc-nc)	Female	8	7.6	105.1	(45.3-207.1)
Female	4	2.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	112	121.7	92	(75.8-110.7)
Male	2	2.8	nc	(nc-nc)	Female	115	117.4	98	(80.9-117.6)
Female	0	1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	17	82.5	(45.1-138.4)					
Female	21	17.1	122.6	(75.9-187.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.3	150.6	(64.8-296.7)	Male	1	3.3	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	18	20.5	87.8	(52-138.8)	Female	0	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	5.9	101.4	(37-220.8)	Female	3	1.9	nc	(nc-nc)
Female	6	7.5	80	(29.2-174.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.4	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	17	18.7	91	(53-145.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	2.6	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	2	nc	(nc-nc)	Female	0	3.2	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	1.6	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	10	9.3	107.1	(51.3-197)	Female	54	68	79.4	(59.7-103.6)
Female	18	10.9	165.3	(97.9-261.3)	Female	62	75.1	82.5	(63.3-105.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.2	nc	(nc-nc)	Male	5	3	165.2	(53.3-385.6)
Female	1	1.3	nc	(nc-nc)	Female	7	2.3	307.8	(123.3-634.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	0.9	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	17	17.8	95.2	(55.5-152.5)	Female	0	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	5.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	18	18.7	96.3	(57-152.2)
Male	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.5	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.8	nc	(nc-nc)	Female	5	4.1	121.6	(39.2-283.9)
Female	2	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	50	63.2	79.2	(58.8-104.4)
Male	0	1.6	nc	(nc-nc)	Female	53	56.4	93.9	(70.3-122.9)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	8	nc	(nc-nc)					
Female	8	7.3	109.6	(47.2-215.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	33.1	81.6	(53.7-118.7)	Male	17	21.3	79.9	(46.5-127.9)
Female	10	12.1	83	(39.7-152.6)	Female	14	16.7	83.8	(45.8-140.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.2	112.4	(45-231.7)	Male	3	5.9	nc	(nc-nc)
Female	5	5.2	96.8	(31.2-226)	Female	3	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1	nc	(nc-nc)	Male	15	18.7	80	(44.8-132)
Female	123	122.6	100.4	(83.4-119.7)	Female	14	15.5	90.3	(49.3-151.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	4.3	232.6	(111.4-427.8)	Male	18	13.9	129.1	(76.5-204)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	37.1	86.3	(59-121.9)	Female	6	11.3	53.2	(19.4-115.9)
Female	35	37.9	92.2	(64.2-128.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	12	8.8	136.2	(70.3-237.9)	Male	98	121.9	80.4	(65.3-98)
Female	1	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	2.6	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	17.3	86.8	(48.6-143.2)	Female	28	28.2	99.5	(66.1-143.7)
Female	10	10	100.3	(48-184.4)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	6	4.8	124.7	(45.5-271.5)	Male	9	12.7	70.9	(32.3-134.6)
Female	2	1.5	nc	(nc-nc)	Female	7	9.4	74.8	(30-154.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	10	10.2	98.3	(47.1-180.8)	Male	58	60.1	96.5	(73.2-124.7)
Female	1	3.5	nc	(nc-nc)	Female	77	61.6	125	(98.7-156.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.3	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	9	7.6	117.8	(53.8-223.7)	Female	3	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	1	0.1	nc	(nc-nc)	Female	12	8.4	143	(73.8-249.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.8	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	0.7	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	4.2	nc	(nc-nc)	Female	29	29.8	97.3	(65.1-139.7)
Female	5	3.7	135.3	(43.6-315.7)	Female	29	25.4	114	(76.3-163.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.2	154.5	(49.8-360.6)	Male	2	2.2	nc	(nc-nc)
Female	0	1	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	17	12.4	136.7	(79.6-218.8)	Female	4	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.8	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	0	3.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.1	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	14	13.5	103.3	(56.4-173.4)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.3	nc	(nc-nc)	Female	2	3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	46	46	100.1	(73.3-133.5)
Male	0	1.1	nc	(nc-nc)	Female	49	40	122.4	(90.6-161.8)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	6.1	nc	(nc-nc)					
Female	6	5.4	111.6	(40.8-242.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	17.5	108.7	(65.4-169.8)	Male	8	11.9	67.3	(29-132.5)
Female	9	6.8	133.2	(60.8-252.9)	Female	7	9.9	70.7	(28.3-145.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.8	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	5	3.1	163.8	(52.8-382.2)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	10.6	103.9	(51.8-185.9)
Female	72	71.6	100.6	(78.7-126.6)	Female	6	8.8	67.9	(24.8-147.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	5	8.1	62	(20-144.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	20.7	86.8	(51.4-137.2)	Female	5	6.5	77.1	(24.9-180)
Female	34	22.1	153.8	(106.5-214.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.8	86.2	(27.8-201.3)
Male	5	4.7	105.5	(34-246.2)	Female	7	6.6	106.2	(42.5-218.8)
Female	2	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	47	65.1	72.3	(53.1-96.1)
Male	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.8	nc	(nc-nc)
Male	9	9.9	91.3	(41.7-173.4)	<u>Testis</u>				
Female	4	5.6	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.6	nc	(nc-nc)	Male	8	4.6	172.2	(74.1-339.3)
Female	0	0.8	nc	(nc-nc)	Female	9	14.2	63.4	(28.9-120.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	7.2	69.6	(22.4-162.4)	Female	16	15.6	102.4	(58.5-166.3)
Female	3	5.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	204	240.6	84.8	(73.5-97.3)
Male	4	5.7	nc	(nc-nc)	Female	238	246.2	96.7	(84.8-109.8)
Female	1	1.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	31.4	79.7	(51.6-117.7)					
Female	34	32.8	103.7	(71.8-144.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	42.6	79.7	(55.2-111.4)	Male	23	27.9	82.4	(52.2-123.7)
Female	10	15.8	63.3	(30.3-116.5)	Female	13	22.5	57.8	(30.7-98.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.4	71.5	(26.1-155.6)	Male	10	7.7	130.2	(62.3-239.4)
Female	8	7	113.9	(49-224.4)	Female	4	6.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	16	24.7	64.8	(37-105.2)
Female	159	163.6	97.2	(82.7-113.5)	Female	15	20.5	73	(40.9-120.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	5.8	154.6	(70.5-293.5)	Male	11	18.5	59.3	(29.6-106.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	46	48.6	94.7	(69.4-126.4)	Female	17	15.1	112.9	(65.7-180.8)
Female	56	50	111.9	(84.5-145.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	17	11.5	148.3	(86.4-237.5)	Male	11	14	78.4	(39.1-140.3)
Female	4	3.2	nc	(nc-nc)	Female	12	15.3	78.5	(40.5-137.2)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	6	3.7	160.9	(58.8-350.3)	Male	13	10.1	128.2	(68.2-219.2)
Female	3	3.1	nc	(nc-nc)	Female	2	6.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	15	22.8	65.9	(36.8-108.6)	Male	5	6	82.7	(26.7-193)
Female	14	13.2	106.1	(57.9-178)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	6.3	nc	(nc-nc)	Female	36	37.4	96.2	(67.3-133.1)
Female	2	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	16.8	71.4	(36.9-124.8)	Male	497	575.1	86.4	(79-94.4)
Female	14	12.5	111.7	(61-187.3)	Female	513	569.1	90.1	(82.5-98.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	13.4	74.6	(35.7-137.2)	<u>All Sites / Types</u>				
Female	3	4.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	73	77.3	94.4	(74-118.7)	<u>All Sites / Types</u>				
Female	73	80.3	90.9	(71.2-114.3)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	17.3	69.5	(35.9-121.4)	Male	18	13	138.7	(82.2-219.3)
Female	3	5.8	nc	(nc-nc)	Female	14	10.4	134.3	(73.4-225.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.3	nc	(nc-nc)	Male	7	3.4	202.9	(81.3-418.1)
Female	4	3.3	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.6	nc	(nc-nc)	Male	14	11.3	123.4	(67.4-207)
Female	91	79.7	114.2	(91.9-140.2)	Female	8	8.5	94.4	(40.7-186.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.2	nc	(nc-nc)	Male	12	9.6	125.3	(64.7-218.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	21.9	91.4	(55.8-141.2)	Female	6	6.8	87.9	(32.1-191.3)
Female	13	19.3	67.3	(35.8-115)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	4	5.3	nc	(nc-nc)	Female	6	6	99.8	(36.4-217.2)
Female	0	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	1.8	nc	(nc-nc)	Female	4	5.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	10	11.5	87.1	(41.7-160.2)	Female	5	4.4	112.4	(36.2-262.4)
Female	2	5.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	3	3	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	9	7.5	119.8	(54.7-227.5)	Female	4	5.6	nc	(nc-nc)
Female	9	5.2	172.1	(78.5-326.6)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	5	6.6	75.3	(24.3-175.8)	Male	30	17.8	168.4	(113.6-240.5)
Female	0	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	29	33.1	87.6	(58.6-125.8)	Female	271	264.6	102.4	(90.6-115.4)
Female	23	31.7	72.6	(46-108.9)	Female				
					252				
					251.6				
					100.2				
					(88.2-113.3)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1	nc	(nc-nc)
Female	8	7.1	113	(48.7-222.7)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	7.5	134.1	(64.2-246.6)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	3	1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	26	25.2	103.1	(67.3-151)
Male	0	0.6	nc	(nc-nc)	Female	12	22.5	53.3	(27.5-93)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	3.3	nc	(nc-nc)					
Female	0	3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	7.4	134.6	(64.4-247.5)	Male	6	5.2	115.3	(42.1-251)
Female	0	2.3	nc	(nc-nc)	Female	8	3.9	206.2	(88.8-406.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	9	4.6	197.6	(90.2-375.1)
Female	41	29.4	139.2	(99.9-188.9)	Female	2	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	8.9	123	(61.3-220.1)	Female	3	2.6	nc	(nc-nc)
Female	5	7.7	65.2	(21-152.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.5	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
Female	3	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	23	30.8	74.6	(47.2-111.9)
Male	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	2	4.5	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.2	nc	(nc-nc)	Male	2	1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	5.9	84.6	(27.3-197.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3	nc	(nc-nc)	Female	6	6.7	89.3	(32.6-194.4)
Female	1	2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	106	107.2	98.9	(80.9-119.6)
Male	2	2.6	nc	(nc-nc)	Female	104	95.4	109	(89.1-132.1)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	13.9	93.5	(49.7-159.9)					
Female	14	12.5	111.7	(61-187.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	16.8	95	(54.3-154.3)	Male	13	10.1	128.1	(68.1-219.1)
Female	5	5.2	95.9	(30.9-223.9)	Female	10	6.9	144	(68.9-264.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.8	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	5	9	55.4	(17.9-129.3)
Female	55	53.3	103.2	(77.8-134.4)	Female	6	6.6	90.3	(33-196.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	18.5	43.2	(18.6-85.1)	Female	1	4.9	nc	(nc-nc)
Female	15	16.6	90.3	(50.5-148.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	5.4	110.3	(40.3-240)
Male	0	4.3	nc	(nc-nc)	Female	7	5.1	138.3	(55.4-285.1)
Female	1	1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	60	58.9	101.9	(77.7-131.1)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.1	nc	(nc-nc)
Male	2	8.2	nc	(nc-nc)	<u>Testis</u>				
Female	3	4.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.3	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	9	66.9	(24.4-145.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	6.2	145.1	(66.2-275.5)	Female	5	12.2	41.1	(13.2-95.8)
Female	11	4	272.9	(136.1-488.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	175	213.7	81.9	(70.2-95)
Male	3	4.9	nc	(nc-nc)	Female	176	183.8	95.7	(82.1-111)
Female	1	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	29.9	70.1	(43.4-107.2)					
Female	26	26.1	99.5	(65-145.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	20.7	125.3	(81.8-183.6)	Male	12	13.4	89.6	(46.2-156.4)
Female	13	6.8	192.1	(102.2-328.5)	Female	14	9.6	146	(79.8-245)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.7	nc	(nc-nc)	Male	5	3.8	132.7	(42.8-309.7)
Female	0	2.9	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	10	11.6	85.9	(41.1-158)
Female	57	73.5	77.6	(58.8-100.5)	Female	13	8.9	146.5	(77.9-250.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	2.5	236.9	(86.5-515.7)	Male	7	9	77.6	(31.1-159.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	23.2	116.2	(76.6-169.1)	Female	4	6.6	nc	(nc-nc)
Female	20	21	95.3	(58.2-147.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	6.8	175.2	(90.4-306.1)
Male	8	5.7	140.1	(60.3-276)	Female	5	6.5	77.1	(24.9-180)
Female	2	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	97	81.1	119.6	(97-146)
Male	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.1	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	5	2.5	196.2	(63.2-457.8)
Male	8	11.1	72.2	(31.1-142.2)	<u>Testis</u>				
Female	8	5.9	136.4	(58.7-268.9)	Male	2	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	3.1	223.3	(89.5-460.2)	Male	8	4.7	170.6	(73.4-336.1)
Female	2	0.9	nc	(nc-nc)	Female	11	13.1	84.2	(42-150.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	7.7	129.3	(61.9-237.9)	Female	18	17.4	103.7	(61.4-163.9)
Female	5	5.2	97	(31.3-226.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	302	280.6	107.6	(95.8-120.5)
Male	5	6.6	76.1	(24.5-177.5)	Female	240	249	96.4	(84.6-109.4)
Female	1	2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	31	38.4	80.8	(54.9-114.7)					
Female	32	35.9	89.2	(61-126)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	20.4	92.9	(55.9-145.1)	Male	23	12.2	188.7	(119.6-283.1)
Female	1	7.4	nc	(nc-nc)	Female	24	9.2	261.3	(167.4-388.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.4	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	5	2.9	172.7	(55.6-402.9)	Female	4	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	8	10.9	73.2	(31.5-144.3)
Female	93	69.7	133.5	(107.7-163.5)	Female	8	9.2	87.4	(37.6-172.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.3	nc	(nc-nc)	Male	6	7.7	77.5	(28.3-168.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	22.4	116.2	(75.9-170.3)	Female	6	6.4	93.4	(34.1-203.4)
Female	28	23.5	119.1	(79.1-172.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	6.6	137.3	(62.6-260.6)
Male	4	5.1	nc	(nc-nc)	Female	5	7.3	68.9	(22.2-160.7)
Female	3	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	70	67.5	103.7	(80.8-131)
Male	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.9	nc	(nc-nc)
Male	6	9.7	62.1	(22.7-135.1)	<u>Testis</u>				
Female	4	5.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	2.7	nc	(nc-nc)	Male	8	3.9	206.3	(88.8-406.4)
Female	0	0.8	nc	(nc-nc)	Female	21	11.3	185.7	(114.9-283.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	7.6	105.5	(45.4-208)	Female	13	15.5	83.6	(44.5-143)
Female	8	5.6	143.5	(61.8-282.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	254	253.6	100.1	(88.2-113.2)
Male	2	5.7	nc	(nc-nc)	Female	296	247.8	119.4	(106.2-133.8)
Female	2	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	35.7	61.6	(38.6-93.3)					
Female	42	36.1	116.4	(83.9-157.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	60.3	89.6	(67.3-116.9)	Male	41	39.4	104.1	(74.7-141.3)
Female	32	23.7	135.2	(92.4-190.8)	Female	40	33.3	120.1	(85.8-163.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	11.6	121	(66.1-203)	Male	15	10.9	137.6	(76.9-226.9)
Female	15	10.2	146.5	(81.9-241.7)	Female	10	9.5	104.9	(50.2-192.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.9	nc	(nc-nc)	Male	46	34.5	133.3	(97.6-177.8)
Female	241	248	97.2	(85.3-110.3)	Female	28	30.7	91.1	(60.5-131.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	8.8	136.2	(70.3-238)	Male	32	26.1	122.8	(84-173.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	72	68.1	105.7	(82.7-133.1)	Female	23	22.6	102	(64.6-153)
Female	86	74.3	115.7	(92.5-142.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	20	19.9	100.7	(61.5-155.6)
Male	22	16.3	135.2	(84.7-204.7)	Female	19	22.8	83.2	(50.1-129.9)
Female	1	4.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	196	226.9	86.4	(74.7-99.4)
Male	8	4.8	167.3	(72-329.7)	<u>Stomach</u>				
Female	3	4.1	nc	(nc-nc)	Male	11	14.3	77	(38.4-137.7)
<u>Kidney & Renal Pelvis</u>					Female	4	9.1	nc	(nc-nc)
Male	35	32.3	108.3	(75.4-150.7)	<u>Testis</u>				
Female	22	20	110.1	(69-166.7)	Male	4	7.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	13	8.9	145.6	(77.4-248.9)	Male	21	14.3	147.3	(91.2-225.3)
Female	3	3	nc	(nc-nc)	Female	58	45.6	127.2	(96.6-164.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	23	23.2	99	(62.7-148.5)	Female	49	57	85.9	(63.5-113.6)
Female	13	18.3	70.9	(37.7-121.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	830	811.9	102.2	(95.4-109.4)
Male	21	18.9	111	(68.7-169.6)	Female	908	855.3	106.2	(99.4-113.3)
Female	9	6.9	129.5	(59.1-245.9)					
<u>Lung and Bronchus</u>									
Male	115	110.4	104.1	(86-125)					
Female	157	122.6	128.1	(108.8-149.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	5	7.2	69.8	(22.5-163)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	7	7.9	88.6	(35.5-182.6)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	18	28	64.4	(38.1-101.8)
Male	0	0.7	nc	(nc-nc)	Female	18	23.6	76.1	(45.1-120.3)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	3.7	nc	(nc-nc)					
Female	1	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	12.3	170.3	(105.4-260.3)	Male	7	8.7	80	(32.1-164.8)
Female	3	4.4	nc	(nc-nc)	Female	15	7.4	203.8	(114-336.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.7	nc	(nc-nc)
Female	41	54	75.9	(54.5-103)	Female	8	6.2	129.3	(55.7-254.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	2.1	284.8	(104-619.9)	Male	5	6.1	82	(26.4-191.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	14.7	122.1	(72.3-193)	Female	3	4.8	nc	(nc-nc)
Female	23	14.2	161.9	(102.6-242.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.2	119.7	(38.6-279.3)
Male	6	3.6	168.5	(61.5-366.8)	Female	2	4.2	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	45	50.9	88.5	(64.5-118.4)
Male	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.7	nc	(nc-nc)
Male	16	7.4	216	(123.4-350.8)	<u>Testis</u>				
Female	3	4.2	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	10	11.3	88.6	(42.4-162.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	5.2	116.3	(42.5-253.1)	Female	17	12.4	137.5	(80-220.1)
Female	3	3.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	196	178.8	109.6	(94.8-126.1)
Male	5	4.3	116.6	(37.6-272)	Female	188	178.4	105.4	(90.9-121.6)
Female	0	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	34	23.1	147.4	(102.1-206)					
Female	30	23.9	125.3	(84.5-178.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	19.5	87	(50.6-139.3)	Male	22	12.2	180.7	(113.2-273.7)
Female	10	7	142.7	(68.3-262.4)	Female	12	9.2	130.7	(67.4-228.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.4	176.5	(64.4-384.1)	Male	6	3.5	173	(63.2-376.6)
Female	4	2.8	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	13	10.7	121.1	(64.4-207.1)
Female	67	70.4	95.1	(73.7-120.8)	Female	9	8.9	101.4	(46.3-192.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.3	nc	(nc-nc)	Male	5	8.1	62	(20-144.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	21.7	73.6	(42-119.5)	Female	5	6.4	77.7	(25-181.3)
Female	21	22.1	94.9	(58.8-145.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	6.4	156.7	(75-288.3)
Male	3	5.2	nc	(nc-nc)	Female	13	6.8	191.1	(101.6-326.8)
Female	1	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	60	71.1	84.4	(64.4-108.7)
Male	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.7	nc	(nc-nc)
Male	9	9.9	90.7	(41.4-172.2)	<u>Testis</u>				
Female	10	5.7	175.6	(84.1-323)	Male	0	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.8	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	11	11.8	93.4	(46.6-167.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	7.3	nc	(nc-nc)	Female	14	16.1	86.7	(47.4-145.5)
Female	5	5.3	94.8	(30.6-221.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	227	254.6	89.1	(77.9-101.5)
Male	7	5.9	117.8	(47.2-242.7)	Female	231	244.4	94.5	(82.7-107.5)
Female	3	2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	35.3	62.3	(39.1-94.4)					
Female	22	35.3	62.3	(39-94.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.2	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	1	1	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	16	12.2	131	(74.8-212.8)	Female	1	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.7	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
Female	7	3.3	212.5	(85.1-437.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.1	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	9	12.4	72.6	(33.1-137.8)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Testis</u>				
Female	3	0.9	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	5	2.9	175.3	(56.5-409)
Female	1	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	29	43.4	66.9	(44.8-96.1)
Male	1	1	nc	(nc-nc)	Female	52	40.1	129.7	(96.8-170.1)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	5.8	nc	(nc-nc)					
Female	5	5.5	91.2	(29.4-212.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	11	72.4	(31.2-142.8)	Male	5	6.4	78.5	(25.3-183.2)
Female	6	4.5	133.3	(48.7-290.1)	Female	3	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	5.8	86.9	(28-202.9)
Female	29	37.3	77.7	(52-111.5)	Female	5	5.4	93	(30-217.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	11.6	68.8	(29.6-135.6)	Female	4	3.7	nc	(nc-nc)
Female	13	14.1	91.9	(48.9-157.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	2.7	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.8	nc	(nc-nc)	Female	59	35.6	165.8	(126.2-213.9)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	4	4.8	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	1.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	4	4	nc	(nc-nc)	Female	5	5.8	86.1	(27.7-200.9)
Female	1	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	2.9	nc	(nc-nc)	Male	3	8.5	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	15	19.1	78.4	(43.8-129.3)	Female	129	133.9	96.3	(80.4-114.4)
Female	19	21.2	89.6	(53.9-139.9)	Female	110	140.9	78.1	(64.2-94.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	21.3	159.7	(110.6-223.2)	Male	11	14.6	75.2	(37.5-134.6)
Female	13	7.6	170.6	(90.7-291.7)	Female	13	11.7	111.3	(59.2-190.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.6	nc	(nc-nc)	Male	3	4	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	7	3.1	225.2	(90.2-464)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	9	12.8	70.1	(32-133.1)
Female	109	87.1	125.2	(102.8-151)	Female	15	10.3	146.1	(81.7-241)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.3	nc	(nc-nc)	Male	9	10.1	89.5	(40.9-170)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	25	95.9	(61.4-142.7)	Female	10	7.8	129	(61.8-237.3)
Female	22	24.4	90.1	(56.5-136.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	7.1	nc	(nc-nc)
Male	5	6	83.7	(27-195.2)	Female	11	7.3	150.2	(74.9-268.7)
Female	0	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	81	84.4	96	(76.2-119.3)
Male	1	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.5	nc	(nc-nc)	Male	6	5.2	115.6	(42.2-251.6)
<u>Kidney & Renal Pelvis</u>					Female	6	3	201.9	(73.7-439.6)
Male	18	12.3	146.1	(86.6-231)	<u>Testis</u>				
Female	7	6.8	103.1	(41.3-212.4)	Male	1	3.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.3	nc	(nc-nc)	Male	8	5.7	140.9	(60.7-277.7)
Female	1	1	nc	(nc-nc)	Female	13	17.2	75.8	(40.3-129.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	8.6	139.1	(71.8-243)	Female	21	19.7	106.8	(66.1-163.3)
Female	5	6.3	79.5	(25.6-185.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	316	299.6	105.5	(94.2-117.8)
Male	5	7.2	69.9	(22.5-163)	Female	339	291.7	116.2	(104.2-129.3)
Female	3	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	52	39.5	131.7	(98.4-172.7)					
Female	49	39.7	123.3	(91.2-163)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	9.3	150.8	(82.4-253.1)	Male	2	6.5	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	5	1.3	384.4	(123.9-897)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.7	nc	(nc-nc)
Female	33	37.1	89	(61.2-124.9)	Female	6	4.4	137.9	(50.4-300.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.4	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	11	136.3	(76.2-224.9)	Female	5	3.3	151.3	(48.8-353.2)
Female	13	10.2	128	(68.1-219)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	3.1	191.9	(70.1-417.8)
Male	3	2.6	nc	(nc-nc)	Female	5	3	164.7	(53.1-384.3)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	39	37.3	104.6	(74.4-143)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	2	5.5	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.9	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.5	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	5	7.6	65.7	(21.2-153.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.8	156.3	(57.1-340.3)	Female	8	8.4	95.5	(41.1-188.2)
Female	1	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	133	132.3	100.5	(84.2-119.1)
Male	3	3.2	nc	(nc-nc)	Female	131	124.1	105.6	(88.2-125.3)
Female	0	1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	17.2	92.8	(53-150.7)					
Female	26	16.9	154	(100.6-225.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	26.6	120.2	(82.2-169.6)	Male	23	16.8	137.2	(86.9-205.8)
Female	3	10.3	nc	(nc-nc)	Female	15	13.4	111.5	(62.4-184)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.9	103.1	(33.2-240.6)	Male	4	4.7	nc	(nc-nc)
Female	10	4.2	238.6	(114.3-438.9)	Female	6	4.1	147.1	(53.7-320.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	14	14.8	94.5	(51.6-158.5)
Female	92	101.6	90.6	(73-111.1)	Female	11	13	84.7	(42.2-151.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.5	nc	(nc-nc)	Male	7	11	63.5	(25.4-130.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	29.8	77.2	(48.9-115.8)	Female	7	9.3	75.2	(30.1-154.9)
Female	30	32.9	91.2	(61.5-130.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	8.7	69.1	(25.2-150.5)
Male	5	7	71.4	(23-166.6)	Female	6	10.1	59.5	(21.7-129.6)
Female	2	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	99	96.2	102.9	(83.7-125.3)
Male	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.5	nc	(nc-nc)	Male	3	6.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	5	4.1	121.8	(39.3-284.3)
Male	12	13.7	87.6	(45.2-153.1)	<u>Testis</u>				
Female	3	8.2	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.8	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	21	17.4	121	(74.9-184.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	10.1	98.9	(47.4-182)	Female	22	22.9	96.3	(60.3-145.8)
Female	6	7.9	75.7	(27.7-164.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	322	348.2	92.5	(82.6-103.1)
Male	7	8.1	86.8	(34.8-178.8)	Female	316	355.6	88.9	(79.3-99.2)
Female	0	2.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	35	48	73	(50.8-101.5)					
Female	40	50.5	79.2	(56.6-107.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	3.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.2	nc	(nc-nc)	Obs	10	15.7	63.8	(30.5-117.3)
Female	0	0	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					Obs				
Male	0	0.4	nc	(nc-nc)	Exp	12.4	72.5	(33.1-137.7)	
Female	0	0.3	nc	(nc-nc)	<u>Liver and Intrahepatic Bile Ducts</u>				
Male	0	0.4	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	2	nc	(nc-nc)
<u>Lung and Bronchus</u>					Female	1	1.6	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	21	104.5	(65.5-158.3)	Male	23	13.6	169.6	(107.5-254.4)
Female	11	7.9	139.5	(69.6-249.7)	Female	21	11	191.7	(118.6-293)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.9	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	6	3.2	189.8	(69.3-413.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	13	11.9	109.4	(58.2-187)
Female	101	81	124.7	(101.6-151.5)	Female	15	10.2	147.5	(82.5-243.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.9	nc	(nc-nc)	Male	10	8.9	112.6	(53.9-207)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	23.7	109.9	(71.7-161)	Female	12	7.4	162.4	(83.8-283.6)
Female	19	24.8	76.6	(46.1-119.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	6.9	159.5	(79.5-285.4)
Male	6	5.6	107.3	(39.2-233.5)	Female	9	7.6	117.9	(53.8-223.8)
Female	0	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	75	77.4	96.9	(76.2-121.5)
Male	1	1.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	3	nc	(nc-nc)
Male	17	11	154.3	(89.8-247)	<u>Testis</u>				
Female	16	6.6	243.9	(139.3-396.2)	Male	4	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	3.1	229.3	(91.9-472.5)	Male	7	4.8	144.9	(58.1-298.6)
Female	1	1	nc	(nc-nc)	Female	14	14.9	93.7	(51.2-157.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	8	125.2	(59.9-230.2)	Female	22	18.5	118.8	(74.5-179.9)
Female	5	6	82.7	(26.6-193)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	319	279.2	114.3	(102.1-127.5)
Male	10	6.4	155.3	(74.4-285.7)	Female	343	281.5	121.9	(109.3-135.5)
Female	2	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	45	38.1	118.1	(86.1-158)					
Female	51	40.4	126.1	(93.9-165.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	49	43.2	113.5	(83.9-150)	Male	35	28	124.9	(87-173.8)
Female	15	16.4	91.3	(51.1-150.6)	Female	18	22.7	79.3	(47-125.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	8.2	85.4	(34.2-175.9)	Male	7	7.7	90.6	(36.3-186.7)
Female	8	7	114.4	(49.3-225.5)	Female	7	6.6	106.5	(42.7-219.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	24	24.6	97.6	(62.5-145.3)
Female	184	166.6	110.5	(95.1-127.6)	Female	27	21.1	127.9	(84.3-186.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.9	134.6	(58-265.3)	Male	23	18	127.6	(80.8-191.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	65	48.3	134.6	(103.9-171.6)	Female	19	15.2	124.6	(75-194.6)
Female	47	51.3	91.7	(67.3-121.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	11	11.4	96.4	(48.1-172.5)	Male	120	157.3	76.3	(63.2-91.2)
Female	1	3.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	3.5	nc	(nc-nc)	Male	7	6	117.4	(47-241.8)
Female	2	2.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	22	22.7	97.1	(60.8-147)	Female	41	38.1	107.5	(77.1-145.8)
Female	19	13.6	139.6	(84-218.1)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	6.2	nc	(nc-nc)	Male	16	16.5	96.7	(55.2-157.1)
Female	4	2	nc	(nc-nc)	Female	16	12.7	126.5	(72.2-205.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	14	13.1	106.7	(58.3-179.1)	Male	104	78.6	132.3	(108.1-160.3)
Female	2	4.7	nc	(nc-nc)	Female	93	84.6	110	(88.8-134.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	180	165.4	108.8	(93.5-125.9)	Male	58	108.7	53.4	(40.5-69)
Female	71	64.8	109.6	(85.6-138.2)	Female	41	94.2	43.5	(31.2-59.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	27	34.1	79.2	(52.2-115.2)	Male	31	29.4	105.3	(71.6-149.5)
Female	27	29.7	91	(59.9-132.4)	Female	18	25.7	70	(41.5-110.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	5.1	97.1	(31.3-226.7)	Male	100	97.1	103	(83.8-125.3)
Female	549	655.5	83.7	(76.9-91.1)	Female	92	84.4	109.1	(87.9-133.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	39	24.7	158.1	(112.4-216.1)	Male	72	70.1	102.7	(80.4-129.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	165	187.8	87.9	(75-102.3)	Female	63	60.9	103.5	(79.5-132.4)
Female	202	207	97.6	(84.6-112)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	46	54	85.1	(62.3-113.6)
Male	50	43.3	115.5	(85.7-152.3)	Female	63	63.1	99.8	(76.7-127.7)
Female	12	13	92	(47.5-160.8)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	554	589.1	94	(86.4-102.2)
Male	16	16.5	97.2	(55.5-157.8)	<u>Stomach</u>				
Female	11	14.1	78.2	(39-140)	Male	42	39.2	107.2	(77.3-145)
<u>Kidney & Renal Pelvis</u>					Female	35	25.7	136.4	(95-189.7)
Male	85	87.1	97.6	(77.9-120.6)	<u>Testis</u>				
Female	55	53.4	103.1	(77.6-134.1)	Male	20	28.7	69.7	(42.6-107.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	20	23.6	84.9	(51.8-131.1)	Male	36	40.8	88.3	(61.8-122.2)
Female	10	7.7	130.7	(62.6-240.4)	Female	113	132.5	85.3	(70.3-102.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	63	67.1	94	(72.2-120.2)	Female	168	147.2	114.1	(97.5-132.8)
Female	51	53	96.3	(71.7-126.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	2144	2207	97.1	(93.1-101.3)
Male	76	50.4	150.7	(118.8-188.7)	Female	2197	2321.5	94.6	(90.7-98.7)
Female	26	18.7	139	(90.8-203.6)					
<u>Lung and Bronchus</u>									
Male	349	295.5	118.1	(106-131.2)					
Female	356	323.5	110	(98.9-122.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	4	6.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	7	6.9	101.4	(40.6-208.9)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	25	23.2	107.8	(69.8-159.2)
Male	1	0.6	nc	(nc-nc)	Female	19	19.7	96.6	(58.1-150.9)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	3.1	162.2	(52.3-378.5)					
Female	1	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	11	109.2	(56.3-190.7)	Male	5	7.6	66.1	(21.3-154.3)
Female	3	4.3	nc	(nc-nc)	Female	6	6.2	97.5	(35.6-212.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	6.7	119.6	(51.5-235.7)
Female	55	46.3	118.8	(89.5-154.6)	Female	0	5.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	13.3	128.1	(74.6-205.1)	Female	3	4.1	nc	(nc-nc)
Female	10	14	71.3	(34.1-131.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.7	135.3	(43.6-315.8)
Male	5	3.1	161.6	(52.1-377.1)	Female	3	4.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	51	43.4	117.6	(87.6-154.6)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	1.7	nc	(nc-nc)
Male	4	6.4	nc	(nc-nc)	<u>Testis</u>				
Female	3	3.6	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	5	8.7	57.7	(18.6-134.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.5	nc	(nc-nc)	Female	4	10.2	nc	(nc-nc)
Female	6	3.4	174.5	(63.7-379.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	163	155	105.2	(89.6-122.6)
Male	1	3.8	nc	(nc-nc)	Female	137	156.9	87.3	(73.3-103.3)
Female	3	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	20	99.8	(60.9-154.2)					
Female	13	21.1	61.7	(32.8-105.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	57	51.1	111.5	(84.5-144.5)	Male	37	28.1	131.6	(92.6-181.4)
Female	32	18.6	172.4	(117.9-243.4)	Female	44	20.4	215.9	(156.8-289.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	6.9	nc	(nc-nc)	Male	11	8.3	131.9	(65.7-235.9)
Female	8	6.3	127.1	(54.7-250.4)	Female	11	7.2	152.9	(76.2-273.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	30	25.1	119.5	(80.6-170.6)
Female	183	154.1	118.8	(102.2-137.3)	Female	19	21.9	86.6	(52.1-135.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.5	nc	(nc-nc)	Male	24	16.3	147.3	(94.3-219.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	45	52.3	86.1	(62.8-115.2)	Female	10	14.7	68	(32.6-125.1)
Female	52	56.6	91.9	(68.6-120.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	16	106.5	(62-170.6)
Male	17	11.9	142.6	(83-228.3)	Female	16	18.2	87.9	(50.2-142.7)
Female	6	3.8	158.6	(57.9-345.2)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	193	154.6	124.8	(107.8-143.7)
Male	7	2.3	308.7	(123.7-636.1)	<u>Stomach</u>				
Female	4	2	nc	(nc-nc)	Male	7	11.2	62.6	(25.1-128.9)
<u>Kidney & Renal Pelvis</u>					Female	6	7.1	84.1	(30.7-183.1)
Male	16	21.1	75.9	(43.3-123.2)	<u>Testis</u>				
Female	11	13.5	81.4	(40.6-145.7)	Male	2	2.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	6.3	nc	(nc-nc)	Male	13	7.6	170.9	(90.9-292.3)
Female	1	2	nc	(nc-nc)	Female	9	21.7	41.5	(18.9-78.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	26	17.4	149.2	(97.4-218.6)	Female	30	35.7	84.1	(56.7-120)
Female	19	12.8	148.1	(89.1-231.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	673	590.8	113.9	(105.5-122.8)
Male	16	12.6	127.1	(72.6-206.5)	Female	627	576.2	108.8	(100.5-117.7)
Female	4	5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	101	88.2	114.5	(93.2-139.1)					
Female	97	91.6	105.9	(85.9-129.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;